IRIS
BANDINI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.282
NA - Nord America 1.072
EU - Europa 893
SA - Sud America 412
AF - Africa 23
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 3.688
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.017
SG - Singapore 449
BR - Brasile 353
CN - Cina 335
HK - Hong Kong 259
SE - Svezia 249
IT - Italia 243
DE - Germania 160
VN - Vietnam 118
RU - Federazione Russa 45
FI - Finlandia 44
GB - Regno Unito 36
CA - Canada 27
AR - Argentina 26
TR - Turchia 26
IN - India 24
PL - Polonia 22
MX - Messico 20
FR - Francia 17
NL - Olanda 16
JP - Giappone 13
ZA - Sudafrica 13
BD - Bangladesh 12
EC - Ecuador 12
ES - Italia 12
AT - Austria 11
IE - Irlanda 11
ID - Indonesia 10
IQ - Iraq 7
LT - Lituania 7
CO - Colombia 6
VE - Venezuela 6
PK - Pakistan 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 4
PY - Paraguay 4
UZ - Uzbekistan 4
BE - Belgio 3
GR - Grecia 3
IR - Iran 3
MA - Marocco 3
NP - Nepal 3
SA - Arabia Saudita 3
AU - Australia 2
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GT - Guatemala 2
KW - Kuwait 2
LV - Lettonia 2
MY - Malesia 2
NI - Nicaragua 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
MK - Macedonia 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
UY - Uruguay 1
Totale 3.688
Salva come PNG Salva come JPEG
Città #
Hong Kong 252
Singapore 221
Dallas 193
Ashburn 128
Shanghai 91
Milan 81
New York 71
Hefei 65
Lawrence 55
Princeton 55
Beijing 53
Ho Chi Minh City 46
Los Angeles 44
São Paulo 31
Boardman 27
Munich 23
Brooklyn 20
Turin 20
Moscow 19
Turku 19
Denver 18
Hanoi 18
Helsinki 18
Rome 16
Warsaw 14
Tekirdağ 13
Tokyo 13
Montreal 12
Orem 12
Poplar 12
Rio de Janeiro 12
Dublin 11
Chicago 10
Nuremberg 10
Santa Clara 10
Boston 9
Florence 9
Johannesburg 9
London 9
Phoenix 8
Seattle 8
Amsterdam 7
Atlanta 7
Caxias do Sul 7
Guangzhou 7
Houston 7
Pune 7
Stockholm 7
Ankara 6
Charlotte 6
Fortaleza 6
Frankfurt am Main 6
Haiphong 6
Hanover 6
Mexico City 6
Salvador 6
Vienna 6
Brasília 5
Bắc Ninh 5
Can Tho 5
Central 5
Chennai 5
Manchester 5
Querétaro 5
Quito 5
Toronto 5
Bari 4
Betim 4
Cabo Frio 4
Cesano Boscone 4
Da Nang 4
Detroit 4
Genoa 4
Guayaquil 4
Lappeenranta 4
Livorno 4
Piracicaba 4
São José 4
Washington 4
Amantea 3
Augusta 3
Baghdad 3
Barueri 3
Biên Hòa 3
Bologna 3
Buenos Aires 3
Buffalo 3
Carapicuíba 3
Columbus 3
Curitiba 3
Erbil 3
Krakow 3
Mariana 3
Mumbai 3
New Delhi 3
Osasco 3
Porto Alegre 3
Rho 3
Ribeirão das Neves 3
San Francisco 3
Totale 2.028
Salva come PNG Salva come JPEG
Nome #
Development of a novel signature integrating clinical, imaging and epigenetic information to tailor pelvic nodal treatment in prostate cancer 302
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 162
Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma 119
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 103
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 99
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 89
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 87
A global approach to improving penile cancer care 84
Causal contributors to tissue stiffness and clinical relevance in urology 75
A risk calculator predicting recurrence in lymph node metastatic penile cancer 71
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 71
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 71
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 70
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 69
Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting 67
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 64
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 64
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer 63
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 62
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 61
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups 60
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 60
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 59
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 59
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 58
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 58
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 55
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 53
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 52
Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy 49
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 49
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 48
Revolutionizing care for rare genitourinary tumours 46
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 45
Targetable gene fusions and aberrations in genitourinary oncology 44
The effect of race on survival after local therapy in metastatic prostate cancer patients 43
Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations 43
Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636–43 43
Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias 41
Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis 41
Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies 41
DNA methylation alterations in prostate cancer: from diagnosis to treatment 40
Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma 40
The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis 39
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma 39
Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer 39
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? 39
The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC) 39
Nomograms in urologic oncology, advantages and disadvantages 37
Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition 37
Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer 36
Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis 36
Prevalence and surgical management of pubic hypertrophy in hypospadias patients: Results from a high-volume surgeon 35
The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer 35
Re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55–65 35
Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines 35
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration 35
The new era of precision urobiome: RE: “Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study” by Chipollini et al 33
Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited 33
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages 32
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study 32
Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? 32
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab 32
Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment 31
Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233–9 31
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 16
null 1
null 1
null 1
null 1
null 1
Totale 3.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.861
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132 0 0 0 0 0 25 7 0 0 0 0 0
2021/202296 0 16 3 32 1 0 2 6 2 4 0 30
2022/2023413 131 99 31 11 3 42 11 46 8 3 13 15
2023/2024365 6 25 38 35 33 67 50 40 4 4 16 47
2024/20251.222 100 50 22 113 49 77 177 165 164 126 65 114
2025/20261.636 227 298 290 447 292 82 0 0 0 0 0 0
Totale 3.773